Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Casirivimab    symbols : TEVJF    save search

New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Published: 2021-11-08 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
| | O: 0.16% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.12% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K twitter stocktwits trandingview |
Health Technology
| | O: 3.88% H: 0.78% C: 0.68%

covid casirivimab phase 3
FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
| | O: 1.2% H: 0.08% C: -0.43%
REGN | $896.27 0.26% 0.25% 500K twitter stocktwits trandingview |
Health Technology
| | O: 1.07% H: 2.19% C: 0.47%

covid treatment fda casirivimab fda acceptance
New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
Published: 2021-09-30 (Crawled : 05:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.02% H: 0.2% C: -0.31%
REGN | $896.27 0.26% 0.25% 500K twitter stocktwits trandingview |
Health Technology
| | O: 0.17% H: 0.96% C: -0.42%

covid results casirivimab covid-19
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
| | O: -0.02% H: 0.2% C: -0.31%
REGN | $896.27 0.26% 0.25% 500K twitter stocktwits trandingview |
Health Technology
| | O: 0.17% H: 0.96% C: -0.42%

covid positive results casirivimab phase 3 trial trial results
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance

EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services

NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services

INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing

WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |


Your saved searches
Save your searches and get alerts when important news are released.